Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Emibetuzumab + Erlotinib||Phase II||Actionable||In a Phase II trial, the combination of Tarceva (erlotinib) and Emibetuzumab (LY2875358) compared to Tarceva (erlotinib) alone did not result in a significantly different median progression-free survival (9.3mo vs 9.5mo, respectively) and median overall survival (34.3mo vs 25.4mo, respectively) in patients with non-small cell lung cancer (PMID: 31622732).||31622732|